Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01417104 · ClinicalTrials.gov registry record · Phase 2
Aliskiren Effect on Aortic Plaque Progression
A Phase 2 study, sponsored by Ohio State University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
NCT01417104 is a Phase 2 study that was terminated before completion, run by Ohio State University. The registered enrollment target is 71 participants.
The verdict
NCT01417104, a Phase 2 study, was terminated before completion, sponsored by Ohio State University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
Study Summary
This study is being done to assess the effectiveness of short term (\~9 months) Aliskiren/Placebo therapy to slow down the progression of atherosclerotic disease in thoracic and abdominal aorta. This will be checked by comparing before and after therapy magnetic resonance imaging (MRI) pictures of the aortic wall. Aliskiren is an FDA approved drug for hypertension but in this study is used for a new indication. Recent studies with animals have shown that Aliskiren therapy reduces the atherosclerotic plaque. Therefore, in this study, the investigators would like to evaluate whether the investigational drug Aliskiren, which is not FDA approved for this indication has the same beneficial effects in people with atherosclerotic disease.
Interventions
- DRUG Placebo
- DRUG Aliskiren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2009-10 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01417104
The ClinicalTrials.gov registry entry for NCT01417104 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01417104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01417104 about?
NCT01417104 is a clinical study titled "Aliskiren Effect on Aortic Plaque Progression". This study is being done to assess the effectiveness of short term (\~9 months) Aliskiren/Placebo therapy to slow down the progression of atherosclerotic disease in thoracic and abdominal aorta. This will be checked by comparing before and after therapy magnetic resonance imaging (MRI) pictures of t...
What is the current status of trial NCT01417104?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2009-10. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01417104?
The interventions under investigation include: Placebo (DRUG), Aliskiren (DRUG).
Who is sponsoring clinical trial NCT01417104?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.